var data={"title":"Sipuleucel-T: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sipuleucel-T: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/416772?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sipuleucel-t-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sipuleucel-T: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10170443\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Provenge</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10170597\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Cellular Immunotherapy, Autologous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181491\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with oral acetaminophen 650 mg and an antihistamine (eg, diphenhydramine 50 mg) ~30 minutes prior to infusion. For autologous use only. Do not infuse until confirmation of product release has been received from the company. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Prostate cancer, metastatic:</b> IV: Each dose contains &ge;50 million autologous CD54+ cells (obtained through leukapheresis) activated with PAP-GM-CSF; administer doses at ~2-week intervals for a total of 3 doses (Kantoff, 2010). If unable to receive a scheduled infusion, an additional leukapheresis procedure will be necessary prior to continuing a course of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181492\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553691\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22553692\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181493\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Acute infusion reaction: Interrupt or slow infusion rate (depending on the severity of infusion reaction); may require acetaminophen, IV H<sub>1</sub> and/or H<sub>2</sub> antagonists, or low-dose meperidine to manage acute symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181496\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Provenge:  (250 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181395\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238293\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Patients may receive Sipuleucel-T at a participating site. Physicians must go through an inservice and register to prescribe the treatment; patients must also complete an enrollment form. Information on registration and enrollment is available at 1-877-336-3736.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181494\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For autologous use only; the identity of the patient must be matched to the patient identifiers on the infusion bag and on the &ldquo;Final Product Disposition Notification&rdquo; prior to infusion. Do not infuse until confirmation of product release is received from the company. Keep the sealed infusion bag in the insulated polyurethane container inside the shipping box until ready for administration. Prior to infusion, inspect bag for signs of leaks (do not administer if leaking) or damage. Gently mix to resuspend contents; inspect for clumps or clotting; small clumps should disperse with the gentle mixing; do not administer if clumps remain. Infusion must begin prior to the expiration date and time; do <b>NOT</b> infuse if expired.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For IV infusion only. Infuse over ~60 minutes; infuse the entire contents of the bag. Do <b>NOT</b> use a cell filter for infusion. For acute infusion reaction, interrupt or slow infusion rate (depending on the severity of infusion reaction); may require acetaminophen, IV H<sub>1</sub> and/or H<sub>2</sub> antagonists, or low-dose meperidine to manage acute symptoms. If infusion is interrupted, keep infusion bag at room temperature; do not resume if bag is retained at room temperature for &gt;3 hours. Observe patient for at least 30 minutes after infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10170508\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prostate cancer, metastatic:</b> Treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181394\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">For autologous use only; patient identity must be matched to the patient identifiers on the infusion bag and on the &ldquo;Cell Product Disposition Form&rdquo; prior to infusion. Healthcare providers should apply universal precautions when handling both the initial leukapheresis product and the activated product.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181399\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Initial infusion-related events usually present within the first 24 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (53%; grades &ge;3: 2%), fatigue (41%; grades &ge;3: 1%), headache (18%; grades &ge;3: &lt;1%), dizziness (12%; grades &ge;3: &lt;1%), pain (12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (22%; grades &ge;3: &lt;1%), vomiting (13% grades &ge;3: &lt;1%), constipation (12%; grades &ge;3: &lt;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic: Anemia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Severe infusion related reaction (71%; grade 3: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (30%; grades &ge;3: 3%), myalgia (12%; grades &ge;3: &lt;1%), weakness (11%; grades &ge;3: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (31%; grades &ge;3: 1%), citrate toxicity (15%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (8% grades &ge;3: &lt;1%), hemorrhagic stroke (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (5%; grades &ge;3: &lt;1%), skin rash (5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (7%), acute ischemic stroke (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (9%; grades &ge;3: &lt;1%), muscle spasm (8%; grades &ge;3: &lt;1%), neck pain (6%), tremor (5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Hematuria (8%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (10%), dyspnea (9%; grades &ge;3: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cerebrovascular accident, eosinophilia, hypotension, myasthenia gravis, myocardial infarction, myositis, paresthesia (grades &ge;3), pulmonary embolism, rhabdomyolysis, sepsis, syncope, transient ischemic attacks, tumor flare, venous thrombosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181577\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181397\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reaction: Acute infusion reactions may occur within 1 day of infusion and are usually mild or moderate for most patients; the incidence of severe reaction may be higher with the second infusion, while the third infusion is associated with a decrease in the incidence of severe reactions. Premedication with oral acetaminophen and diphenhydramine is recommended. Depending on the severity of the infusion reaction, interrupt or slow infusion rate; in clinical trials, acetaminophen, intravenous (IV) H<sub>1</sub> and/or H<sub>2</sub> antagonists, and low-dose meperidine were used to manage acute symptoms. Symptoms of acute infusion reaction may include chills, rigor, fever, bronchospasm, dyspnea, hypoxia, hypertension, tachycardia, syncope, hypotension, joint or muscle aches, nausea, vomiting, dizziness, fatigue, headache, and weakness; fever and chills usually resolved within 2 days. Observe patient for at least 30 minutes after infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Deep venous thrombosis (DVT) and pulmonary embolism occurred following sipuleucel-T infusion (postmarketing reports), usually in patients with multiple risk factors for thromboembolism. Use with caution in patients at risk for thromboembolic events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vascular disorders: Cerebrovascular (hemorrhagic and ischemic stroke) and cardiovascular events (myocardial infarction [MI]) have occurred; transient ischemic attacks have been reported following infusion (postmarketing reports). Such events usually occurred in patients with multiple risk factors for cerebrovascular or cardiovascular incidents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Closely monitor during infusion in patients with cardiac conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: Closely monitor during infusion in patients with pulmonary conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Androgen deprivation therapy: In clinical trials, patients who had androgen deprivation therapy without prior bilateral orchiectomy were continued on gonadal suppression with a luteinizing hormone-releasing hormone (LHRH) agonist (Higano, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy: Concurrent use with chemotherapy has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppressive therapy: Concurrent use with immunosuppressives (eg, corticosteroids) has not been studied; may alter the efficacy and/or safety of sipuleucel-T. Carefully evaluate patients for appropriateness of reducing or discontinuing immunosuppressive agents prior to treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For autologous use only. Patient identity must be matched to the patient identifiers on the infusion bag and on the Final Product Disposition Notification (provided by manufacturer) prior to infusion. Confirmation of product release must be received from the manufacturer prior to infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Handling precautions: Apply universal precautions for product handling. Sipuleucel-T is not routinely tested for transmissible infectious diseases; patient-specific leukapheresis collection and activated product may have a risk for infectious disease transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sterility testing: Preliminary sterility testing is done based on a 2-day incubation period. Final (7-day incubation) testing is not available until after administration; physicians will be notified if 7-day sterility tests are positive for microbial contamination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Treatment delays: If unable to receive a scheduled reinfusion, an additional leukapheresis procedure may be required; advise patients of this possibility before treatment initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300046\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10191787\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9916&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Sipuleucel-T.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181396\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Not indicated for use in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181576\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15383294\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for infusion reaction during and for at least 30 minutes after infusion; monitor closely during infusion for patients with cardiovascular and pulmonary disease; monitor for thromboembolic and vascular events.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10181488\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Autologous cellular immunotherapy which stimulates an immune response against an antigen (PAP) expressed in most prostate cancer tissues. Peripheral blood is collected (~3 days prior to infusion) from the patient via leukapheresis, from which peripheral blood mononuclear cells (PBMCs) are isolated. Antigen presenting cell (APC) precursors, consisting of CD54-positive cells that include dendritic cells, are isolated from the PBMCs. The APCs are then activated (<i>in vitro</i>) with a recombinant human fusion protein, PAP-GM-CSF (also termed PA2024), composed of an antigen specific for prostate cancer, prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF) and cultured for ~40 hours. The final product, sipuleucel-T, is reinfused into the patient,  inducing T-cell immunity to tumors that express PAP. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23777338\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Provenge (EE, LT, MT, NL, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beer TM, Bernstein GT, Corman JM, et al, &ldquo;Randomized Trial of Autologous Cellular Immunotherapy With Sipuleucel-T In Androgen-Dependent Prostate Cancer,&rdquo; <i>Clin Cancer Res</i>, 2011, 17(13):4558-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/21558406/pubmed\" target=\"_blank\" id=\"21558406\">21558406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burch PA, Breen JK, Bruckner JC, et al, &ldquo;Priming Tissue-Specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer,&rdquo; <i>Clin Cancer Res</i>, 2000, 6(6):2175-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/10873066/pubmed\" target=\"_blank\" id=\"10873066\">10873066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burch PA, Croghan GA, Gastineau DA, et al, &ldquo;Immunotherapy (APC8015, Provenge&reg;) Targeting Prostatic Acid Phosphatase Can Induce Durable Remission of Metastatic Androgen-Independent Prostate Cancer: A Phase 2 Trial,&rdquo; <i>Prostate</i>, 2004, 60(3):197-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/15176049/pubmed\" target=\"_blank\" id=\"15176049\">15176049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higano CS, Schellhammer PF, Small EJ, et al, &ldquo;Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer,&rdquo; <i>Cancer</i>, 2009, 115(16):3670-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/19536890/pubmed\" target=\"_blank\" id=\"19536890\">19536890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantoff PW, Higano CS, Shore ND, et al, &ldquo;Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer,&rdquo; <i>N Engl J Med,</i> 2010, 363(5):411-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/20818862/pubmed\" target=\"_blank\" id=\"20818862\">20818862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel PH and Kockler DR, &ldquo;Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer,&rdquo; <i>Ann Pharmacother</i>, 2008, 42(1):91-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/18094343/pubmed\" target=\"_blank\" id=\"18094343\">18094343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provenge (sipuleucel-T) [prescribing information]. Seattle, WA: Dendreon Corporation; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Small EJ, Fratesi P, Reese DM, et al, &ldquo;Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells,&ldquo; <i>J Clin Oncol</i>, 2000, 18(23):3894-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/11099318/pubmed\" target=\"_blank\" id=\"11099318\">11099318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Small EJ, Schellhammer PF, Higano CS, et al, &ldquo;Placebo-Controlled Phase III Trial of Immunologic Therapy With Sipuleucel-T (APC8015) in Patients With Metastatic, Asymptomatic Hormone Refractory Prostate Cancer,&rdquo; <i>J Clin Oncol</i>, 2006, 24(19):3089-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sipuleucel-t-drug-information/abstract-text/16809734/pubmed\" target=\"_blank\" id=\"16809734\">16809734</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9916 Version 71.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10170443\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10170597\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10181491\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F10181492\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22553691\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22553692\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F10181493\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10181496\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F10181395\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11238293\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10181494\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10170508\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10181394\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10181399\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10181577\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10181397\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300046\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10191787\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10181396\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10181576\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15383294\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10181488\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23777338\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9916|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sipuleucel-t-patient-drug-information\" class=\"drug drug_patient\">Sipuleucel-T: Patient drug information</a></li></ul></div></div>","javascript":null}